sciencenewsnet.in

Alzheimer’s Drug Development Pipeline: Promising Therapies, Pharma Investment Drive Momentum in Clinical Trials

May 25, 2023 sarah JonasResearch Results

According to the newly released “Alzheimer’s Disease Drug Development Pipeline: 2023,” there are currently 187 clinical trials in the Alzheimer’s drug development pipeline – the most ever on record. This momentum is driven in part by greater investment from the pharma industry and a bump in biologic therapies – particularly monoclonal antibodies – that were central to the success of both recent FDA-approved drugs.

The annual report spots trends in clinical trial design and outcome measures, and also investigate the types of agents and biological targets that are being pursued.

Mayo Clinic Conference on Brain Health and Dementia to welcome people living with dementia, caregivers and health care providers

September 8, 2021 sarah JonasAnnouncement

The inaugural Mayo Clinic Conference on Brain Health and Dementia will be held virtually on Oct. 29 from 9:15 a.m. to 2:15 p.m. CDT with an optional workshop to follow. The event is a collaboration among Mayo Clinic, AARP and the Alzheimer’s Association.

Us Against Alzheimer’s advocacy group must reveal financial conflict of interest to FDA, says Dr. Leslie Norins of Alzheimer’s Germ Quest 

February 16, 2021 sarah JonasFeature

Alzheimer’s advocacy groups taint their credibility by not revealing conflicts when they lobby FDA for drug approval

Case Western Reserve University-led team finds that people with dementia at higher risk for COVID-19

February 9, 2021 sarah JonasResearch Results

A study led by Case Western Reserve University researchers found that patients with dementia were at a significantly increased risk for COVID-19—and the risk was higher still for African Americans with dementia.